Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FADS1 | O60427 | 1/20 | 0.30 |
| ▸ | CAMK2D | Q13557 | 1/20 | 0.30 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.30 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.30 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.30 |
| ▸ | CSNK2A3 | Q8NEV1 | 1/20 | 0.30 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL544111 | 0.74 | MEN1 (0.50) | FADS1CAMK2D | |
| SCHEMBL6431056 | 0.74 | PLA2G7 (0.44) | — | |
| SCHEMBL4934839 | 0.72 | FADS1 (0.31) | FADS1CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL544521 | 0.71 | KIF11 (0.45) | CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL543776 | 0.71 | KMT2A (0.47) | CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL4532117 | 0.71 | EGFR (0.50) | — | |
| SCHEMBL543837 | 0.70 | HDAC3 (0.42) | CSNK2A2CSNK2BCSNK2A1CSNK2A3 | |
| SCHEMBL729232 | 0.69 | FLT1 (0.46) | CSNK2A1 | |
| SCHEMBL6237657 | 0.69 | AURKA (0.57) | — | |
| SCHEMBL543690 | 0.69 | ROCK1 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | AB SCIENCE | 2008-06-19 | — | — | US | disclosed |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | AB SCIENCE (FR) | 2008-01-03 | — | — | US | disclosed |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | MOUSSY ALAIN | 2007-10-25 | — | — | US | disclosed |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | AB SCIENCE | 2007-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146585-A1 | Use Of C-Kit Inhibitors For Treating Inflammatory Muscle Disorders Including Myositis And Muscular Dystrophy | KIT, CPA3, CMA1 | FADS1 4619/4885CAMK2D 405/4885CSNK2A2 588/4885 |
| US-20070225293-A1 | Use of C-Kit Inhibitors for Treating Fibrosis | KIT, CPA3, CMA1 | FADS1 4616/4885CAMK2D 1752/4885CSNK2A2 1272/4885 |
| US-20080004279-A1 | Use of C-Kit Inhibitors for Treating Plasmodium Related Diseases | KIT, JAK3, MAP3K3 | FADS1 4805/4885CAMK2D 756/4885CSNK2A2 1160/4885 |
| US-20070249628-A1 | Use of Mast Cells Inhibitors for Treating Patients Exposed to Chemical or Biological Weapons | KIT, CPA3, CMA1 | FADS1 3938/4885CAMK2D 1290/4885CSNK2A2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.